Physician profile
Imaduddin Syed Hashmi
NPI 1013198886
$3,949.81
in general payments reported to CMS, 2019-2025
32 companies · $88.09 in 2025
The $88.09 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,880 · 2020: $481 · 2021: $231 · 2022: $406 · 2023: $414 · 2024: $450 · 2025: $88.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Titan Pharmaceuticals, INC. | $524.19 | 2019 | |
| Orexo US, INC. | $396.25 | 2019-2025 | Zubsolv |
| Amgen INC. | $379.14 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $368.23 | 2019-2024 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $325.13 | 2019-2020 | |
| Novo Nordisk INC | $287.92 | 2019-2020 | |
| Alkermes, INC. | $258.46 | 2022-2024 | Lybalvi |
| Indivior INC. | $152.48 | 2019-2024 | Sublocade |
| Merck Sharp & Dohme LLC | $133.11 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $102.46 | 2019-2021 | |
| Gilead Sciences, INC. | $101.85 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.23 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $78.36 | 2019-2024 | Airsupra |
| Nalpropion Pharmaceuticals LLC | $78.31 | 2019 | |
| Allergan, INC. | $77.41 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $75.59 | 2019-2022 | |
| Abbvie INC. | $65.22 | 2020-2023 | |
| Kowa Pharmaceuticals America, INC. | $52.43 | 2022-2023 | Seglentis |
| Biohaven Pharmaceutical Holding Company LTD. | $46.62 | 2022 | |
| Glaxosmithkline, LLC. | $44.78 | 2023-2024 | Arexvy |
| Regeneron Healthcare Solutions, INC. | $38.67 | 2023 | Dupixent |
| Amarin Pharma, INC. | $37.24 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.76 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $30.59 | 2019 | |
| Pfizer INC. | $30.13 | 2019 | |
| Braeburn INC. | $25.57 | 2025 | Brixadi |
| Tactile Systems Technology INC | $25.54 | 2025 | Flexitouch Plus, Nimbl |
| Protega Pharmaceutials INC | $21.03 | 2024 | Roxybond |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Genentech USA, INC. | $19.90 | 2019 | |
| Hologic Sales and Service, LLC | $16.22 | 2025 | Aptima |
| E.R. Squibb & Sons, L.L.C. | $15.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imaduddin Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.